TRINITY BIOTECH PLC TRIB

Healthcare SIC 2835 - In Vitro & In Vivo Diagnostic Substances NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —$61.6M$56.8M$62.5M$81.1M$102.0M$90.4M$97.0M$99.1M$99.6M
Operating income —-$21.2M-$27.0M-$19.3M$3.9M$82.0K-$24.1M-$20.2M-$37.7M-$39.8M
Net income —-$31.2M-$36.9M-$43.6M-$1.9M-$6.0M-$29.0M-$22.7M-$38.7M-$38.6M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets —$103.3M$59.4M$92.1M$118.9M$130.4M$131.1M$151.7M$193.0M$249.6M
Total equity —-$35.2M-$23.9M-$2.2M-$319.0K-$2.2M$4.7M$44.1M$65.2M$108.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001554855-26-000848.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Total liabilities
  • Stock-based compensation
  • Revenue
Total liabilities, Stock-based compensation, Revenue by fiscal year, in US dollars The same figures are in the table below this chart. 0 50M 100M 150M Revenue, FY2016: 99.6M Revenue, FY2017: 99.1M Revenue, FY2018: 97M Revenue, FY2019: 90.4M Revenue, FY2020: 102M Revenue, FY2021: 81.1M Revenue, FY2022: 62.5M Revenue, FY2023: 56.8M Revenue, FY2024: 61.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Total liabilities — — — — — — — — — —
Stock-based compensation — — — — — — — — — —
Revenue $99.6M $99.1M $97.0M $90.4M $102.0M $81.1M $62.5M $56.8M $61.6M —

Others in SIC 2835

TickerCompanyMarket capP/ERevenue growth
IDXX IDEXX LABORATORIES INC /DE $42.18B 40.9x 10.4%
LNTH Lantheus Holdings, Inc. $6.59B 29.6x 0.5%
CLDX Celldex Therapeutics, Inc. $3.12B — -78.0%
NEOG NEOGEN CORP $2.58B — -2.7%
NTLA Intellia Therapeutics, Inc. $1.79B — 16.9%
QDEL QuidelOrtho Corp $958.0M — -1.9%
ACHV ACHIEVE LIFE SCIENCES, INC. $873.6M — —
TKNO Alpha Teknova, Inc. $371.5M — 7.4%